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A total of 11 children (five males and six females) with
hypergranular type of acute promyelocytic leukemia (APML)
were treated with intravenous arsenic trioxide (As2O3) between
December 1998 and October 2003. Eight cycles of As2O3
(0.15 mg/kg/day) were administered (induction, consolidation
and six cycles of maintenance) over a period of 12 months. The
median WBC count at diagnosis was 3400/mm3 (range: 800–
9800). In all, 10 patients (91%) achieved hematological remis-
sion at a mean duration of 48 days (range: 41–60) with all 10
patients achieving molecular remission at a median duration of
81 days (range: 64–109). Toxicity was minimal with leukocytosis
in six patients, ichthyosis and hyperpigmentation of skin in five
and mild peripheral neuropathy in one patient. One patient who
relapsed 6 months after completing therapy achieved a second
hematological and molecular remission with As2O3. With a
median follow-up of 30 months (range: 4–62), the overall (OS)
survival is 91% with a relapse-free survival (RFS) of 81%. As2O3
achieves hematological and molecular remission in majority of
newly diagnosed children with APML with minimal toxicity, but
long-term follow-up is required to evaluate late effects of As2O3
and study the minimum dose and duration required for a
sustained remission.
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Introduction
The incidence of acute promyelocytic leukemia (APML) in
children varies between 8 and 30% of all cases of AML
depending upon the geographic location.1 The frontline therapy
for APML using a combination of ATRA and chemotherapy has
shown initial remission rates of 69–97% with event-free survival
(EFS) ranging between 64 and 77% in studies from various
countries including India.2–6 Treatment with ATRA, however, is
not financially possible for all patients in economically poor
countries and hence alternative therapeutic strategies have been
explored. Arsenic trioxide (As2O3) was initially used in the
treatment of relapsed APML with remission rates of 80–90% and
long-term DFS of 60–80%.7,8 Subsequent reports from various
centers including ours showed that As2O3 as primary therapy can
achieve remission rates in 70–80% of patients.9–11 There is,
however, very limited data on its use in children and we share our
experience with its use in newly diagnosed children with APML.
Patients and methods
Patients
A total of 11 children with newly diagnosed APML, who could
not afford treatment with ATRA and hence were treated with
As2O3 between December 1998 and October 2003, were
included in this study. All patients met the morphological
criteria for diagnosis according to the French–American–British
(FAB) classification. The diagnosis was confirmed using con-
ventional cytogenetics and either fluorescent in situ hybridiza-
tion (FISH) for 15;17 or reverse transcriptase polymerase chain
reaction (RT-PCR) for detecting PML-RARa transcripts. The
initial three patients were treated as a part of an institutional
study protocol after approval by the Institutional Review Board
but subsequently since 2001, As2O3 has become part of the
standard treatment protocol at our institution for patients with
APML who cannot afford treatment with ATRA.
Treatment with As2O3
Intravenous As2O3 was prepared by dissolving specified
quantities of As2O3 (AR grade (99.8% purity) from SD Fine
Chemicals Ltd, Boisar, India) in sterile pyrogen-free distilled
water at 601C for 20 min. No other additives were used in its
preparation. The final product had a concentration of 1 mg/ml
and was supplied as 10-ml vials. As2O3 was administered at a
dose of 0.15 mg/kg/day as an intravenous infusion in 500 ml of
5% dextrose saline over 4 h. Induction therapy was given till
achievement of hematological remission (or a maximum of 60
days) followed by consolidation therapy for 28 days after a gap
of 4 weeks. Maintenance therapy consisted of 10 days of As2O3
every month for 6 months (Figure 1).
Toxicity
Patients were monitored for toxicity particularly with regard to
cardiac and hepatic function. Leukocytosis (WBC counts
45000/mm3) during induction therapy was treated with
hydroxyurea. If WBC counts were not under control with
hydroxyurea, single or multiple doses of anthracyclines were
used. Cutaneous examination was performed regularly during
treatment and on subsequent follow-up. If patients had
symptoms of peripheral neuropathy, nerve conduction studies
were carried out to document the presence of a neuropathy.
Hematological monitoring and support
Complete blood counts, prothrombin time (PT), activated partial
thromboplastin time (APTT), liver and renal functions were
closely monitored. Platelet transfusions were given to maintain
platelet counts more than 20 000/mm3. Fresh frozen plasma
(15 ml/kg) was infused if there was significant coagulopathy
even in the absence of clinical bleeding. Bone marrow
examination was carried out to assess remission once abnormal
promyelocytes had cleared from peripheral blood along with
normal platelet counts. Hematological remission (CR) was
defined as absence of abnormal promyelocytes from peripheral
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blood with ANC 41000/mm3, normal platelet counts and
absence of abnormal promyelocytes in the bone marrow.
Molecular monitoring
RT-PCR for detecting PML-RARa´ transcripts was performed, as
previously described by van Dongen et al,12 at diagnosis, at the
time of attaining hematological CR, prior to consolidation
therapy, twice during maintenance therapy (3 months apart) and
subsequently every 6 months. With a nested amplification, the
RT-PCR had a sensitivity of 104 for bcr-3 transcripts and 103
for bcr-1 transcripts from cells of APML patients.
Results
Patients
There were five male and six female subjects with a median age
of 12 years (range: 6–14). All had the hypergranular type of
APML. The median WBC and platelet counts at diagnosis were
3.4 109/l (range: 0.8–9.8) and 18 109/l (range: 6–242)
respectively. None of the 11 patients had any significant
coagulopathy at diagnosis. All patients were RT-PCR positive
for PML-RARa transcripts, while only nine showed the presence
of t(15;17) on routine karyotyping. Two patients showed
additional chromosomal abnormalities on routine karyotyping.
Hematological remission
A total of 10 patients (91%) achieved hematological remission,
while one patient expired on day 5 of therapy due to an
intracranial hemorrhage. The mean duration to achieving
hematological remission was 48 days (range: 41–60). Eight
patients (80%) have completed treatment, while two (20%) are
still on treatment.
Toxicity
Leukocytosis during induction therapy was seen in six (60%)
patients and occurred at a mean interval of 9 days (range: 2–15)
after initiation of therapy. The median peak WBC count in these
six patients was 29 109/l (range: 16.9–45.8). Hydroxyurea was
used in all six patients for a mean duration of 12 days (range:
4–18) with a median cumulative dose of 415 mg/kg (range:
54–815). One patient received a single dose of anthracycline
(Mitoxantrone) to achieve rapid reduction in blood counts. In
three patients, As2O3 had to be temporarily discontinued for a
mean of 3 days (range: 2–5), but it was successfully restarted in
all patients. Dexamethasone was not used in any of the patients
with leukocytosis. The median number of red cell and platelet
units transfused during induction therapy were 3 (range: 0–16)
and 11 (range: 0–27), respectively. Five patients (45%) devel-
oped coagulopathy during treatment requiring the use of fresh
frozen plasma (FFP) over a mean duration of 4 days (range: 2–6).
No patients required transfusions during consolidation and
maintenance therapy. No cardiac or hepatic toxicity was seen.
Minor toxicities seen included ichthyosis and hyperpigmenta-
tion of skin (seen in five patients) that resolved following
cessation of therapy and mild reversible peripheral neuropathy
in one patient (Table 1).
Treatment with As2O3
A total of eight cycles of As2O3 was administered to patients
who have completed treatment. The mean duration of hospital
stay during induction therapy was 14 days (range: 0–26). One
patient, who had normal platelet counts at diagnosis, had the
entire induction therapy administered on an outpatient basis.
None of the patients required admission during their consolida-
tion or maintenance cycles. The mean dose of As2O3 used
during induction was 359 mg (range: 180–600) amounting to a
mean dose of 9.1 mg/kg (range: 7.1–12.2). The cumulative dose
of As2O3 used in patients who have completed treatment was
962 mg (range: 655–1480) amounting to a mean dose of 26 mg/
kg (range: 21–30).
INDUCTION THERAPY
As2O3 (0.15 mg/kg/day) administered daily till
hematological CR or maximum of 60 days
4 week interval
4 week interval
CONSOLIDATION THERAPY
As2O3 administered once daily for 28 days
As2O3 administered once daily for 10 days
MAINTENANCE THERAPY
every month for 6 months
Figure 1 Protocol for treatment of patients with APML with As2O3.
Table 1 Patient characteristics, survival and complications
Patient
no.
Age/
sex
Counts at
diagnosis
(109/l)
Remission
status
Complications Follow-up
(months)
1 14/F 1.6 CR NIL 62
2 14/F 1.4 CR I 47
3 7/F 9.8 CR L, C, I 43
4 12/M 1.5 CR NIL 32
5 13/M 0.8 CR L, C, PN 30
6 6/M 1.6 CR then relapse I 22
7 11/F 5.7 EXPIRED DAY 5 L 0.5 E
8 14/M 3.3 CR L, C 21
9 14/F 6.1 CR I 13
10 15/M 2.0 CR L, C 8
11 13/F 3.6 CR L, C 3
L, leukocytosis; C, coagulopathy; I, ichthyosis/hyperpigmentation of
skin; PN, peripheral neuropathy.
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Molecular remission
Nine patients (81.8%) had the bcr-1 isoform, while one patient
each had the bcr-2 and bcr-3 isoform. All 10 patients (100%)
who achieved hematological remission also achieved molecular
remission. The median time to achieving molecular remission
was 81 days (range: 64–109). A total of nine patients (90%) were
RT-PCR transcript negative for PML-RARa at the end of
consolidation therapy, while one patient (10%) became RT-
PCR transcript negative during maintenance therapy.
Follow-up
One patient had a hematological relapse 6 months after
completion of therapy. He had complex cytogenetic abnorm-
alities along with a t(15;17) on routine karyotyping at diagnosis.
He achieved a second hematological and molecular remission
following repeat induction therapy with As2O3 and is presently
on consolidation therapy. With a median follow-up duration of
30 months (range: 3–60), the leukemia-free survival (EFS) is 81%
with an overall survival (OS) of 91% (Figures 2 and 3).
Discussion
Children with APML have a good chance of cure following
treatment with ATRA and chemotherapy. However, financial
constraints preclude the use of ATRA in the majority of patients
in economically poor countries and hence effective alternative
therapies are necessary.
Treatment with As2O3 achieves remission rates of more than
90%, which is similar to data from children treated with ATRA
and chemotherapy.2,3 There is however no data regarding the
use of As2O3 as primary therapy in children. Ma Jun et al in their
study of 62 children with relapsed APML showed remission rates
of 81% with a 7-year DFS of 65% (Blood 2001; abstract 3119).
The high remission rates coupled with ease of administration
and the minimal toxicity seen during treatment makes As2O3 an
attractive option in children. The intravenous formulations of
As2O3 may have an advantage even in infants and toddlers with
APML, where ATRA may be difficult to administer because of
the difficulty in solubilization of ATRA capsules. The short
duration of hospital stay during induction therapy and the
absence of need for hospital admission during consolidation and
maintenance therapy also adds to the therapeutic value of
arsenic. This therapeutic efficacy of As2O3 is even more
meaningful for developing countries since the cost of treatment
with As2O3 (US $2000) is a fraction of the cost of treatment with
ATRA (US $15 000) since no local formulations of ATRA exist.
This data is, however, preliminary since the median duration of
follow-up in our study is only 30 months and hence we are
unable to comment on the long-term survival with As2O3 and
late toxicity if any. This report is the first to look at the use of
intravenous As2O3 in children with newly diagnosed APML.
In conclusion, As2O3 achieves hematological and molecular
remission in a majority of children with newly diagnosed APML.
The ease of administration coupled with minimal toxicity makes
it an attractive option in children. Long-term follow-up however
is required to assess long-term remission and late side effects in
children.
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Figure 2 Overall survival in 11 children with APML treated with
As2O3.
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Figure 3 Event-free survival in 11 children with APML treated with
As2O3.
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